Ahmed Elmaadawi, MD
Psychiatry · Phoenix, AZNPI 1114189305
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,870 of the $32,441 with a category attached, or 82.8%. Johnson & Johnson accounts for 96.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $16,449 and has fallen 99.8% since, to $37 in 2024. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $499.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$31K
- Neuronetics, Inc.$413
- Livanova USA, Inc.$295
- Neurocrine Biosciences, Inc.$147
- Otsuka America Pharmaceutical, Inc.$51
- Tris Pharma Inc$42
- plus $138 from 7 others
Across 147 payments — averaging $2465.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$242K
- Neurocrine Biosciences, Inc.$68K
- Janssen Research & Development, LLC$49K
- Bioxcel Therapeutics, Inc.$3K
What the payments were for
- Consulting fees$2,4137%
- Speaking & faculty fees$26,87083%
- Travel & lodging$1,7956%
- Food & beverage$1,3634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $31,355 |
| Neuronetics, Inc. | 1 | $413 |
| Livanova USA, Inc. | 7 | $295 |
| Neurocrine Biosciences, Inc. | 2 | $147 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Tris Pharma Inc | 3 | $42 |
| Lundbeck LLC | 2 | $36 |
| AbbVie | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$30,909
- NEUROSTAR TMS THERAPY$413
- INGREZZA$130
- VNS - Symmetry$123
How this compares
$32,441 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 52 | $296 |
| Duloxetine Hcl | 13 | $139 |
| Trazodone Hcl | 17 | $66 |
| Sertraline Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Eric ReimanPhoenix$157K
- Padma AkingPhoenix$44K
- Amnon KahanePhoenix$18K
- Aaron ClayPhoenix$14K
- Joel ParkerPhoenix$11K
- Ivan EngelPhoenix$10K
- Holly HendinPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.